Efficacy and safety of tislelizumab in patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis
{{output}}
Background: Tislelizumab, a PD-1-targeting monoclonal antibody, can potentially treat advanced esophageal squamous cell carcinoma (ESCC). Using pooled clinical data, this study evaluates Tislelizumab's efficacy and safety in adv... ...
